集体诉讼事件 - 集体诉讼代表在2024年2月2日左右公司首次公开募股中根据发售文件购买或收购Alto Neuroscience Inc普通股的投资者 [1] - 集体诉讼也涵盖在2024年2月2日至2024年10月22日期间购买或收购Alto证券的投资者 [1] - 诉讼涉及纽约证券交易所代码为ANRO的Alto Neuroscience Inc公司 [1]

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Alto (ANRO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Alto between February 2, 2024 and October 22, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Brag ...

集体诉讼案件 - 诉讼由Gross Law Firm代表在2024年2月2日至2024年10月22日期间购买Alto Neuroscience Inc (NYSE: ANRO)证券的股东提起 [3] - 指控公司在集体诉讼期间发布重大虚假和/或误导性陈述 未能披露其产品管线ALTO-100治疗重度抑郁症的疗效低于向投资者传达的水平 [4] - 诉讼涵盖通过公司2024年2月2日左右进行的首次公开发行相关发行文件购买普通股的投资者 [3] 公司产品管线问题 - ALTO-100的临床、监管和商业前景被夸大 导致公司业务和/或财务前景被高估 [4] - 公司公开声明在相关时间存在重大虚假和误导性内容 [4] 股东参与程序 - 股东注册截止日期为2025年9月19日 参与本案无需成本或义务 [5] - 注册股东将通过投资组合监控软件获得案件生命周期内的状态更新 [5] - 任命首席原告并非参与任何赔偿的先决条件 [1]

Accessibility StatementSkip Navigation NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influencers ...

诉讼事件概述 - 律师事务所Bragar Eagel & Squire代表投资者对Alto Neuroscience Inc提起集体诉讼 案件在美国加州北区联邦地区法院立案[8] - 诉讼针对2024年2月2日至2024年10月22日期间购买或收购Alto证券的所有投资者[8] - 投资者申请作为首席原告的截止日期为2025年9月19日[8] 指控内容 - 公司IPO支持文件被指控为疏忽准备[8] - 公司未披露ALTO-100治疗重度抑郁症(MDD)的效果低于向投资者宣传的水平[8] - ALTO-100的临床、监管和商业前景被夸大 导致公司业务及财务前景表述不实[8] 股价影响 - 2024年10月22日公司公布ALTO-100二期试验未达到主要终点[8] - 次日股价单日下跌10.17美元 跌幅达69.99% 收盘价报4.36美元[8] 公司产品进展 - ALTO-100二期试验主要终点指标为MADRS量表评分较基线变化 但未能显著优于安慰剂组[8] - 该结果直接导致公司核心产品管线价值重估[8] 投资者参与方式 - 律师事务所提供免费法律咨询 投资者可通过电话(212) 355-4648或邮箱investigations@bespc.com联系[1][4][9] - 投资者可在线提交参与表格 无需承担费用或义务[4]

Alto Neuroscience (NYSE:ANRO) FY Conference September 17, 2025 01:20 PM ET Company ParticipantsAmit Etkin - Founder, President, Chairman & CEOAthena Chin - Biotechnology Equity Research AssociateConference Call ParticipantsRitu Baral - MD & Senior Biotechnology AnalystRitu BaralGood afternoon, everyone. Thank you for joining us for the Alto Neuroscience Fireside Chat here at the TD Cowen New Mechanisms in Neuropsychiatry and Epilepsy virtual conference. I'm covering analyst Ritu Biral, and joining me is my ...

诉讼背景 - Levi & Korsinsky律所通知Alto Neuroscience Inc（NYSE: ANRO）投资者涉及证券集体诉讼[1] - 诉讼旨在为因涉嫌证券欺诈而遭受损失的投资者挽回损失[2] 集体范围 - 集体包括2024年2月2日左右根据公司IPO发行文件购买或收购Alto普通股的个人和实体[2] - 集体还包括在2024年2月2日至2024年10月22日期间（含首尾两日）购买或收购Alto证券的所有人员[2] 指控内容 - 公司产品管线ALTO-100治疗重度抑郁症的疗效低于管理层向投资者传达的水平[3] - ALTO-100的临床、监管和商业前景被夸大[3] - 公司业务和/或财务前景因此被高估[3] - 公司公开声明在相关时间存在重大虚假和误导性[3] 程序信息 - 受影响投资者可在2025年9月19日前向法院申请担任首席原告[4] - 集体成员可能无需支付自付费用即可获得补偿[4]

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO): (i) pursuant and/or traceable to Alto’s initial public offering conducted on or about February 2, 2024 (the “IPO”); and/or (ii) securities between February 2, 2024 and October 22, 2024, both dates inclusive (the “Class Period”), of the important September 19, 2025 lead plaintiff deadline. SO WHAT: If you purchased Alto securities yo ...

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/alto-neuroscience-inc-loss-submission-form/?id=166908&from=3 CLASS PERIOD: ...